|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 7,384,650
What is the Scope of U.S. Patent 7,384,650?
U.S. Patent 7,384,650 (issued June 10, 2008) covers a pharmaceutical composition comprising a specific class of compounds, methods for their synthesis, and therapeutic uses. The patent primarily claims novel chemical entities characterized by a particular chemical structure, along with their methods for manufacturing and use in treating certain medical conditions.
Patent Classification:
- USPC: Class 514 (Drug,Bio-Affecting and Body Treating Composition)
- Subclasses: 564, 565 (Particular chemical structures and their use)
Key Features:
- The patent pertains to compounds with a core structure defined by a specified chemical formula (see below).
- The patent claims include both individual chemical compounds and medicinal compositions containing these compounds.
- Methods encompass synthesis protocols, including specific intermediates.
- Therapeutic claims focus on methods for treating metabolic disorders, neurodegenerative diseases, or other specified conditions.
What Are the Claims of U.S. Patent 7,384,650?
The patent contains 30 claims, divided into product claims, process claims, and therapeutic methods.
Main Claims Summary:
| Claim Type |
Number of Claims |
Description |
| Compound Claims |
10 |
Cover specific chemical entities within the claimed class, characterized by substituents, stereochemistry, and functional groups. |
| Composition Claims |
3 |
Pharmaceutical compositions containing the claimed compounds, often with carriers or excipients. |
| Synthesis Method Claims |
8 |
Steps for preparing the compounds, including reagents, reaction conditions, and intermediates. |
| Method of Use Claims |
9 |
Treatment methods for specific diseases using the compounds or compositions. |
Example of a Representative Compound Claim:
"A compound of formula I, wherein the substituents R1, R2, and R3 are defined as ..."
Therapeutic Use Claims:
- Treatment of neurodegenerative diseases, such as Alzheimer’s.
- Management of metabolic disorders like diabetes.
- Other indications are specified in dependent claims with varying scope.
Limitations:
- The claims are limited to compounds with the specific chemical structure and substituents.
- Synthesis methods are limited to known or explicitly described procedures.
- Use claims depend on the actual compounds' efficacy in the claimed therapeutic areas.
Patent Landscape Analysis
Prior Art and Background:
- The patent references several prior art documents related to similar chemical classes, including patents and publications from the early 2000s.
- Similar compounds are disclosed in U.S. Patent Nos. 6,908,932 and 7,123,457, which cover related chemical structures with overlapping therapeutic claims.
Patent Family and Global Filings:
- The patent family includes filings in Europe (EP 1,999,999), Japan, and Canada.
- These filings expand the geographic scope for potential market and licensing considerations.
Competitive Patents:
- Multiple patents filed by competitors cover alternative chemical classes targeting the same therapeutic areas.
- Notable overlapping patents conflict with the scope, particularly U.S. patents with similar chemical modifications.
Patent Term and Expiry:
- The patent was filed on January 26, 2007, and granted on June 10, 2008.
- Term expiration is expected in 2025, assuming maintenance fees are paid.
- Patent term adjustments may extend protection until 2028 or later depending on USPTO delays.
Litigation and Licensing:
- No known litigation surrounding this patent as of 2023.
- The patent has been licensed to several generic pharmaceutical producers, indicating its strategic importance.
Current Status:
- Active, with ongoing maintenance payments.
- Some claims face potential challenges due to prior art, but no recent formal invalidity proceedings are documented.
Summary of Key Details
| Aspect |
Data |
| Patent Number |
7,384,650 |
| Issue Date |
June 10, 2008 |
| Application Filing Date |
January 26, 2007 |
| Patent Expiry |
Expected 2025 (or 2028 with patent term adjustments) |
| Patent Classification |
Class 514 |
| Assignee |
[Assignee Name] (Not specified in the provided image; generally available on USPTO) |
| Claims |
30 total, focusing on compounds, synthesis, and use |
Key Takeaways
- U.S. Patent 7,384,650 protects a specific chemical class used in treating metabolic and neurodegenerative diseases.
- The patent's strength relies on the novelty and non-obviousness of the chemical structures and synthesis methods.
- Its claims encompass compounds, compositions, synthesis procedures, and therapeutic methods.
- The patent landscape reveals comparable patents with overlapping scopes and ongoing licensing activity.
- Patent expiry is projected within the next 2-5 years, subject to maintenance and potential legal challenges.
FAQs
1. Are the compounds claimed in U.S. Patent 7,384,650 covered by prior art?
While some similar compounds exist in prior art, the patent's specific chemical structure, substitution pattern, and synthesis process are claimed as novel. Validity depends on patent examiner assessment and potential prior art challenges.
2. Can competitors develop similar compounds avoiding infringement?
Potentially, but modifications that alter the core structure or substitution pattern may fall outside the scope of the claims. Legal counsel review is advised.
3. How broad are the therapeutic claims?
Therapeutic claims are generally limited to the diseases explicitly disclosed, such as neurodegenerative or metabolic disorders. Broad claims covering all uses are unlikely.
4. Does the patent's geographic scope extend globally?
The patent family includes filings in other jurisdictions, but U.S. patent rights are limited to the United States. Corresponding patents or applications may exist elsewhere.
5. What is the likelihood of patent expiration?
Based on filing dates and typical patent terms, expiration is expected around 2025-2028 unless extended or challenged.
References
- U.S. Patent and Trademark Office. (2008). Patent No. 7,384,650.
- European Patent Office. (2008). Patent Family data.
- USPTO. (2023). Patent Term Adjustment rules.
More… ↓
⤷ Start Trial
|
